Personal Home Page

http://www.mdanderson.org/care_centers/gyn/display.cfm?id=71D6CE89-FD6A-4CCB-B309A915E39644B6&pn=CB797B39-7868-11D4-AEC400508BDCCE3A&method=displayfull

Articles in Scholarly Journals [Incomplete List]

1. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
   Clinical Cancer Research, vol. 14, no. 3, pp. 797–803, 2008
2. Taxol Increases the Amount and T Cell Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
   Cancer Research, vol. 67, no. 17, pp. 8378–8387, 2007
3. Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells
   Clinical Cancer Research, vol. 12, no. 21, pp. 6557–6564, 2006
4. Prostate Tumor Cells Infected with a Recombinant Influenza Virus Expressing a Truncated NS1 Protein Activate Cytolytic CD8+ Cells To Recognize Noninfected Tumor Cells
   Journal of Virology, vol. 80, no. 1, pp. 383–394, 2006
5. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model
   Cancer Gene Therapy, vol. 13, no. 8, Article ID 7700954, 8 pages, 2006
6. Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death
   Cancer Research, vol. 65, no. 7, pp. 2930–2937, 2005
7. Functional Idiotopes: Tumor Antigen-Directed Expression of CD8+ T-Cell Epitopes Nested in Unique NH2-terminal VH Sequence of Antiidiotypic Antibodies?
   Cancer Research, vol. 65, no. 14, pp. 6001–6004, 2005
8. Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
   Journal of Clinical Oncology, vol. 23, no. 30, pp. 7536–7545, 2005
9. Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
   Cancer Research, vol. 64, no. 15, pp. 5481–5488, 2004
10. BRAK/CXCL14 Is a Potent Inhibitor of Angiogenesis and a Chemotactic Factor for Immature Dendritic Cells
    Cancer Research, vol. 64, no. 22, pp. 8262–8270, 2004
11. Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients
    Journal of Clinical Immunology, vol. 24, no. 4, pp. 449–461, 2004
12. Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene
    Journal of Virology, vol. 77, no. 13, pp. 7411–7424, 2003
13. Axillary Lymph Node Cellular Immune Response to HER-2/neu Peptides in Patients with Carcinoma of the Breast
    Journal of Interferon Cytokine Research, vol. 22, no. 5, pp. 583–592, 2002
14. Molecular and Cellular Biochemistry, vol. 217, no. 1/2, pp. 21–33, 2001
15. Biochemistry, vol. 39, no. 33, pp. 10319–10329, 2000
16. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
    Cancer Immunology, Immunotherapy, vol. 49, no. 9, pp. 459–468, 2000
17. Reduced Recognition of Metastatic Melanoma Cells by Autologous MART-1 Specific CTL: Relationship to TAP Expression
    Journal of Immunotherapy, vol. 23, no. 1, pp. 28–35, 2000
18. Secretion of CXC Chemokine IP-10 by Peripheral Blood Mononuclear Cells from Healthy Donors and Breast Cancer Patients Stimulated with HER-2 Peptides
    Journal of Interferon Cytokine Research, vol. 20, no. 4, pp. 391–401, 2000
19. HER-2/ neu peptide specificity in the recognition of HLA-A2 by natural killer cells
    Cancer Immunology, Immunotherapy, vol. 48, no. 7, pp. 401–410, 1999
20. Biochemistry, vol. 38, no. 40, pp. 13244–13251, 1999
21. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides
    Annals of Surgical Oncology, vol. 5, no. 8, pp. 743–750, 1998
22. Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex
    Molecular Immunology, vol. 35, no. 17, pp. 1121–1133, 1998
23. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
    Journal of Experimental Medicine, vol. 181, no. 6, pp. 2109–2117, 1995
24. Erratum
    Scandinavian Journal of Immunology, vol. 41, no. 1, pp. 102–102, 1995
25. Characterization of T-Cell Receptor Vbeta Repertoire in Ovarian Tumour-Reacting CD3+ CD8+ CD4- CTL Lines
    Scandinavian Journal of Immunology, vol. 40, no. 6, pp. 591–600, 1994
26. Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study
    International Journal of Gynecological Cancer, vol. 4, no. 2, pp. 101–110, 1994
27. Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro
    Cellular Immunology, vol. 157, no. 2, pp. 415–427, 1994
28. T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of Cancer
    Clinical Immunology and Immunopathology, vol. 66, no. 2, pp. 91–106, 1993
29. Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene
    Cellular Immunology, vol. 151, no. 1, pp. 225–234, 1993
30. Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones
    Scandinavian Journal of Immunology, vol. 37, no. 4, pp. 413–424, 1993
31. ?/d T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors
    European Journal of Immunology, vol. 22, no. 3, pp. 679–687, 1992
32. T-cell recognition of oncogene products: A new strategy for immunotherapy
    Molecular Carcinogenesis, vol. 6, no. 2, pp. 77–82, 1992
33. Induction of interleukin-2 receptor by tumor necrosis factor a on cultured ovarian tumor-associated lymphocytes
    Cancer Immunology Immunotherapy, vol. 35, no. 2, pp. 83–91, 1992
34. IL-2-Dependent Murine T-Cell Lines and Clones Expressing Gamma/Delta T-Cell Antigen Receptors. I, Functional and Biochemical Characterization
    Scandinavian Journal of Immunology, vol. 34, no. 6, pp. 779–794, 1991
35. T Cell Responses to Ovarian Tumor Vaccines: Identification and Significance for Future Immunotherapy
    International Reviews of Immunology, vol. 7, no. 4, pp. 349–364, 1991
36. Inhibition of protein kinase C and calmodulin by the geometric isomerscis- andtrans-tamoxifen
    Biopolymers, vol. 29, no. 1, pp. 97–104, 1990
37. Inhibition of IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat by a novel peptide inhibitor of protein kinase C
    Cellular Immunology, vol. 131, no. 1, pp. 242–252, 1990
38. OKT4 monoclonal antibody-induced activation of an autoreactive T-cell clone
    Cellular Immunology, vol. 123, no. 1, pp. 244–252, 1989
39. Molecular Heterogeneity of gamma delta T-Cell Antigen Receptors Expressed by CD4- CD8- T-Cell Clones from Normal Donors: Both Disulfide- and Non-Disulfide-Linked Receptors are delta TCS1+
    Proceedings of the National Academy of Sciences, vol. 86, no. 7, pp. 2326–2330, 1989
40. Identification of a Second T-Cell Antigen Receptor in Human and Mouse by an Anti-Peptide gamma -Chain-Specific Monoclonal Antibody
    Proceedings of the National Academy of Sciences, vol. 84, no. 12, pp. 4244–4248, 1987